Incyte has received European Commission approval for Zynyz (retifanlimab) in combination with carboplatin and paclitaxel as a ...

Professor Günter Höglinger, Lead Investigator of the Mascot trial, said: “Completing randomization of a global Phase 3 trial in MSA is a significant achievement for the field.” He added: “Advancing ...

The Oxford-based biotechnology company Theolytics has been awarded €8 million in non-dilutive grant funding from Horizon ...

HUTCHMED has initiated a global phase 1/2a clinical trial of HMPL‑A580, its second antibody‑targeted therapy conjugate, in ...

The approvals are supported by the REAL8 study, which showed Sogroya was non‑inferior to daily growth hormone therapy across all three indications. Adverse reactions occurring in at least 10% of ...

Bioxytran has announced encouraging results from a randomized, double‑blind, placebo‑controlled phase 1b/2a study of its oral ...

The Briefing Room – what next for healthcare communications?

Finally, there are many risks associated with longer stays: infections; blood clots; muscle weakening and pressure sores, to ...

AlzeCure Pharma has announced that the European Medicines Agency has granted orphan drug status to ACD440, its clinical‑stage ...

Dismantling health stigma – examining the role for pharma ...

AI is creating a new market where the super employee is king ...

The NHS in 2026 is facing a familiar but intensifying oncology challenge. Our data at HSJ Information shows rising incidence, ...